What is claimed is:

1. Use of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) in the manufacture of at least one medicament for reducing the incidence of one or more asthma exacerbations in a subject suffering from severe asthma, wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising heavy chain complementarity determining region (HCDR) sequences of SEQ ID NOs: 148, 150, and 152, and a light chain comprising light chain complementarity determining region (LCDR) sequences of SEQ ID NOs: 156, 158, and 160.

2. The use according to claim 1, wherein the asthma exacerbation is selected from the group consisting of:

(a) a 30% or greater reduction from baseline in morning peak expiratory flow (PEF) on two consecutive days;

(b) six or more additional reliever puffs of albuterol or levalbuterol in a 24 hour period (compared to baseline) on two consecutive days; and

(c) a deterioration of asthma requiring:

(i) systemic (oral and/or parenteral) steroid treatment, or

(ii) an increase in inhaled corticosteroids to at least 4 times the last dose received prior to discontinuation, or

(iii) hospitalization.

3. Use of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) in the manufacture of at least one medicament for improving one or more asthma-associated parameter(s) in a subject suffering from severe asthma, wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising heavy chain complementarity determining region (HCDR) sequences of SEQ ID NOs: 148, 150, and 152, and a light chain comprising light chain complementarity determining region (LCDR) sequences of SEQ ID NOs: 156, 158, and 160.

4. The use according to claim 3, wherein the improvement in an asthma-associated parameter is selected from the group consisting of:

(a) an increase from baseline of forced expiratory volume in 1 second (FEV1) of at least 0.10 L;

(b) an increase from baseline of morning peak expiratory flow rate (AM PEF) of at least 10.0 L/min;

(c) an increase from baseline of evening peak expiratory flow rate (PM PEF) of at least 1.0 L/min;

(d) a decrease from baseline of daily albuterol/levalbuterol use of at least 1 inhalation/day;

(e) a decrease from baseline of five-item Asthma Control Questionnaire (ACQ5) score of at least 0.5 points;

(f) a decrease from baseline of nighttime awakenings (no. of times per night) measured daily of at least 0.2 times per night; and

(g) a decrease from baseline of 22-item Sino-Nasal Outcome Test (SNOT-22) score of at least 5 points.

5. Use of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) in the manufacture of at least one medicament for increasing FEV1 in liters in a subject suffering from severe asthma, wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising heavy chain complementarity determining region (HCDR) sequences of SEQ ID NOs: 148, 150, and 152, and a light chain comprising light chain complementarity determining region (LCDR) sequences of SEQ ID NOs: 156, 158, and 160.

6. The use according to any one of claims 1-5, wherein the medicament is formulated for administration to the subject as an initial dose followed by one or more secondary doses.

7. The use according to claim 6, wherein the initial and secondary doses are about 75 mg to about 600 mg of the antibody or antigen-binding fragment thereof.

8. The use according to any one of claims 1-7, wherein the medicament is formulated for administration to the subject systemically, intravenously, or intranasally.

9. The use according to any one of claims 1-7, wherein the medicament is formulated for administration to the subject subcutaneously.

10. The use according to claim 9, wherein the medicament is formulated for administration to the subject using an autoinjector, a needle and syringe, or a prefilled pen delivery device.

11. The use according to any one of claims 1-10, wherein said medicament is formulated for administration with a background therapy selected from the group consisting of a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a steroid, a leukotriene inhibitor, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, an anti-fungal agent, and a combination thereof.

12. The use according to any one of claims 1-10, wherein said medicament is formulated for administration with a background therapy comprising an inhaled corticosteroids (ICS) and/or a long-acting beta-agonist (LABA).

13. The use according to any one of claims 1-12, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair of SEQ ID NOs: 162/164.

14. The use according to claim 13, wherein the antibody is dupilumab.

15. The use according to any one of claims 1-14, wherein the subject has asthma with Type 2 inflammation.

16. The use according to claim 15, wherein the subject has elevated blood eosinophils and/or an elevated level of fractional exhaled nitric oxide (FeNO).

17. The use according to claim 16, wherein the subject has a blood eosinophil level of at least 300 cells per microliter, and/or a sputum eosinophil level of at least 3%.

18. The use according to any one of claims 1-17, wherein the medicament is an add-on maintenance treatment.

19. The use according to any one of claims 1-18, wherein the subject is at least 6 years old.